Navigation Links
Notre Dame study explores the potential benefits and threats of nanotechnology research
Date:1/25/2013

Every day scientists learn more about how the world works at the smallest scales. While this knowledge has the potential to help others, it's possible that the same discoveries can also be used in ways that cause widespread harm.

A new article in the journal Nanomedicine, born out of a Federal Bureau of Investigation workshop held at the University of Notre Dame in September 2012, tackles this complex "dual-use" aspect of nanotechnology research.

"The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment" says Kathleen Eggleson, a research scientist in Notre Dame's Center for Nano Science and Technology and the author of the study.

"But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the 'dual-use dilemma.'"

The report examines the potential for nano-sized particles (which are measured in billionths of a meter) to breach the blood-brain barrier, the tightly knit layers of cells that afford the brain the highest level of protectionfrom microorganisms, harmful molecules, etc.in the human body. Some neuroscientists are purposefully engineering nanoparticles that can cross the blood-brain barrier (BBB) so as to deliver medicines in a targeted and controlled way directly to diseased parts of the brain.

At the same time, the report notes, "nanoparticles designed to cross the BBB constitute a serious threatin the context of combat." For example, it is theorized that "aerosol delivery" of some nano-engineered agent in "a crowded indoor space" could cause serious harm to many people at once.

The problem of dual-use research was highlighted last year when controversy erupted over the publication of findings that indicate how, with a handful modifications, the H5N1 influenza virus ("bird flu") can be altered in a way that would enable it to be transmitted between mammalian populations.

After a self-imposed one-year moratorium on this research, several laboratories around the world announced that they will restart the work in early 2013.

The FBI is actively responding to these developments in the scientific community.

"The law enforcement-security community seeks to strengthen the existing dialogue with researchers," William So of the FBI's Biological Countermeasures Unit says in the study.

"Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities[and] create effective safeguards for science and national interests."

The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety aspects of their research and to act to protect society when necessary, argues Eggleson.

"The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity's benefit," she says.

"Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science."


'/>"/>

Contact: Kathleen Eggleson
keggleso@nd.edu
574-631-1229
University of Notre Dame
Source:Eurekalert

Related biology technology :

1. Notre Dame researchers demonstrate new DNA detection technique
2. Notre Dame researchers develop paint-on solar cells
3. Nanotrees harvest the suns energy to turn water into hydrogen fuel
4. Notre Dame paper examines nanotechnology-related safety and ethics problem
5. Notre Dame to be part of $194 million university research center network
6. Positive Clinical Study Results for BSPs HyperQ Technology
7. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
8. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
9. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
10. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
11. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... 2017 /PRNewswire/ - The Fight Against Cancer Innovation Trust ... are pleased to report that Fusion Pharmaceuticals Inc. (Fusion) ... & Johnson Innovation – JJDC, Inc. (JJDC) as the ... TPG Biotechnology Partners, and Genesys Capital, as well as ... ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
Breaking Biology News(10 mins):